Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma

por Dummer, Reinhard, Michielin, Olivier, Nägeli, Mirjam Chantal, M. Goldinger, Simone, Campigotto, Federico, Kriemler-Krahn, Ulrike, Schmid, Herbert, Pedroncelli, Alberto, Micaletto, Sara, Schadendorf, Dirk
Publicado 2018